Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

First Posted Date
2023-10-04
Last Posted Date
2024-01-23
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
45
Registration Number
NCT06066216

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

First Posted Date
2023-10-03
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
50
Registration Number
NCT06064097
Locations
🇺🇸

Lurie Children's Hospital-Chicago, Chicago, Illinois, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 40 locations

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

First Posted Date
2023-09-28
Last Posted Date
2024-10-28
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
64
Registration Number
NCT06057935
Locations
🇺🇸

University of Chicago (Data Collection Only), Chicago, Illinois, United States

🇺🇸

University of Michigan (Data Collection Only), Ann Arbor, Michigan, United States

🇺🇸

University of Nebraska (Data collection only), Omaha, Nebraska, United States

and more 10 locations

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

First Posted Date
2023-09-28
Last Posted Date
2024-07-18
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Target Recruit Count
18
Registration Number
NCT06056310
Locations
🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

🇺🇸

Montefiore Medical Center PRIME, Bronx, New York, United States

🇧🇪

Universitair Ziekenhuis Gent - Medical Oncology, Gent, Belgium

and more 20 locations

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

First Posted Date
2023-09-28
Last Posted Date
2023-09-28
Lead Sponsor
Tang-Du Hospital
Target Recruit Count
20
Registration Number
NCT06055738
Locations
🇨🇳

Hongxi Zhao, Xi'an, Shaanxi, China

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

First Posted Date
2023-09-28
Last Posted Date
2024-12-20
Lead Sponsor
Genmab
Target Recruit Count
42
Registration Number
NCT06057038
Locations
🇯🇵

National Cancer Center East, Kashiwa, Japan

🇯🇵

National Cancer Center Hospital, Tokyo, Japan

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

First Posted Date
2023-09-22
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
27
Registration Number
NCT06050252
Locations
🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

🇺🇸

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

UCHealth University of Colorado Hospital, Aurora, Colorado, United States

and more 39 locations

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

First Posted Date
2023-09-21
Last Posted Date
2024-08-02
Lead Sponsor
Nataliya Uboha
Target Recruit Count
39
Registration Number
NCT06048133
Locations
🇺🇸

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

🇺🇸

University of Michigan Health System, Ann Arbor, Michigan, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 1 locations

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

First Posted Date
2023-09-21
Last Posted Date
2023-09-21
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
30
Registration Number
NCT06048926
Locations
🇨🇳

The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

First Posted Date
2023-09-18
Last Posted Date
2024-10-31
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
54
Registration Number
NCT06040970
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy